Posted byOrthoEx Posted in
Posted on Jun 26, 2018

FREMONT, Calif. – June 26, 2018 – Ceterix Orthopaedics, Inc., a leader in the development of cutting-edge surgical tools for orthopaedic surgeons, today announced the issuance of U.S. Patent No. 10,004,492 related to the company’s method of placing a suture around a tear to repair a damaged meniscus, adding to the company’s already expansive intellectual property portfolio.

Ceterix’s new patent further protects the company’s technology enabling surgeons to arthroscopically repair soft tissue injuries in the knee using minimally invasive techniques. This is the second set of method claims describing Ceterix’s proprietary Circumferential Compression Stitch (CCS), a suture method that provides uniform, anatomic compression of meniscus tears that was not possible to do previously given the tight constraints of the knee.

“Whether you are setting a broken bone or suturing a laceration, injuries heal best when the tissue edges are perfectly lined up and repaired without gaps,” says Dr. Justin Saliman, founder and chief medical officer of Ceterix. “For the first time, orthopaedic surgeons can now apply this principle to meniscus tears with NovoStitch® Meniscal Repair Systems. We believe that by enabling simultaneous compression of the femoral and tibial sides of meniscus tears, the Ceterix technology can provide surgeons with greater confidence to repair tears that would have previously been considered non-repairable.”[i],[ii]

“The invention of delivering a Circumferential Compression Stitch within the tight constraints of the knee may be the biggest innovation in meniscal repair in the last 15 years,” says John McCutcheon, president and CEO of Ceterix. “We are committed to expanding options for surgeons to preserve the meniscus and protect normal knee function in their patients.”